SCHEMBL3135564

SCHEMBL3135564

CCN1C(=O)S/C(=C\c2ccc(-c3cccc(Cl)c3)o2)C1=S

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.60
▸ MAP3K5 Q99683 3/20 0.58
▸ DUSP3 P51452 1/20 0.58
▸ GSK3A P49840 1/20 0.57
▸ GSK3B P49841 1/20 0.57
▸ MEN1 O00255 6/20 0.54
▸ POLB P06746 6/20 0.54
▸ KMT2A Q03164 6/20 0.54
▸ HPGD P15428 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ BLM P54132 2/20 0.52
▸ PLA2G1B P04054 1/20 0.52
▸ GFER P55789 1/20 0.52
▸ ATG4B Q9Y4P1 1/20 0.52
▸ PIM1 P11309 6/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ LMNA P02545 1/20 0.50
▸ PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3135572 1.00 MAPT (0.60) MAPTMAP3K5DUSP3GSK3AGSK3B
SCHEMBL3135576 1.00 MAPT (0.60) MAPTMAP3K5DUSP3GSK3AGSK3B
SCHEMBL3131284 0.88 MEN1 (0.48) MAPTMAP3K5DUSP3MEN1POLB
SCHEMBL3131271 0.88 MEN1 (0.48) MAPTMAP3K5DUSP3MEN1POLB
SCHEMBL3131279 0.88 MEN1 (0.48) MAPTMAP3K5DUSP3MEN1POLB
SCHEMBL3133014 0.87 ITGB2 (0.60) MAPTMEN1POLBKMT2AALDH1A1
SCHEMBL3133011 0.87 ITGB2 (0.60) MAPTMEN1POLBKMT2AALDH1A1
SCHEMBL3133007 0.87 ITGB2 (0.60) MAPTMEN1POLBKMT2AALDH1A1
SCHEMBL3123752 0.86 PIK3CG (0.59) MAPTMAP3K5DUSP3MEN1POLB
SCHEMBL3123759 0.86 PIK3CG (0.59) MAPTMAP3K5DUSP3MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US claimed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO claimed
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 MAPT 3126/4885MAP3K5 3869/4885DUSP3 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback